search.noResults

search.searching

dataCollection.invalidEmail
note.createNoteMessage

search.noResults

search.searching

orderForm.title

orderForm.productCode
orderForm.description
orderForm.quantity
orderForm.itemPrice
orderForm.price
orderForm.totalPrice
orderForm.deliveryDetails.billingAddress
orderForm.deliveryDetails.deliveryAddress
orderForm.noItems
RESEARCH ▶▶▶


New protocol for creating vaccines


Researchers at The Pirbright Institute have published their procedures on video for creating a vaccine that protects against Marek’s disease and infectious bursal disease (IBD) using a CRISPR/Cas 9 gene editing system.


BY TONY MCDOUGAL B


oth viruses cause highly infectious diseases of poultry and can cause huge economic losses around the globe. For example, Marek’s costs the worldwide poultry industry US$ 1bn annually,


according to studies released in 2017. Herpesvirus of turkeys (HVT) is an ideal vector for the generation of recombinant vaccines against a number of disease, using bacterial artifi- cial chromosome mutagenesis or conventional recombina- tion methods. The clustered regularly interspaced palindromic repeats (CRISPR)/Cas9 system has been success- fully used in many settings for gene editing, including the manipulation of several large DNA virus genomes. Research carried out at Pirbight’s Viral Oncogenesis group by UK and Chinese scientists utilises fast and accurate gene ed- iting tools to insert an IBD virus gene into the Marek’s vac- cine virus. This results in the creation of a recombinant vac- cine, which allows the single vaccine to protect against both diseases simultaneously. Speaking in the video journal JoVE, professor Venugopal Nair, head of the Viral Oncogenesis group, said developing the protocol was not easy but the hard work shown by the team had paid off. “Extensive work went into defining the correct quantities and timings of each step, and it has taken the last two years to streamline the process.” “We now have a procedure that is highly efficient and represents a vast improvement on previous techniques,” he added.


Although other recombinant vaccines exist that protect against both viruses, the methods for producing them are lengthy and not as reliable. The new system, demonstrated in JoVE, is precise and allows vaccines to be developed rap- idly, which improve the capacity for responding to changing outbreak situations. There are video sections covering trans- fection and infection, harvesting and purification of the HVT


recombinant virus, excision of the fluorescent reporter gene via the Cre-lox system, plaque purification, verification of the recombinant HVT, the stability of the recombinant virus and a results section covering analysis of the generated recombi- nant avian herpesvirus vectors. The method’s flexibility also offers the potential to expand and protect against three or four diseases, including influenza, which remains a major challenge to both producers and human health. Sharing the methodology through video allows scientists to see how the recombinant vaccine is created step-by-step. This could benefit other laboratories which are looking to use CRISPR/Cas9 systems to target other poultry diseases such as Newcastle disease virus. Dr Yongxiu Yao, senior scientists in the group who led the work, added: “The development of new vaccines using this approach will be highly beneficial for the poultry industry to protect against multiple poultry diseases.”


▶ POULTRY WORLD | No. 2, 2019


The Pirbight re- searchers share the methodolo- gy through video to allow scientists to see how the recom- binant vaccine is created step-by- step.


33


PHOTO: RUUD PLOEG FOTOGRAFIE


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36